What Is Fiasp Insulin? Uses, Side Effects & More

Fiasp is a fast-acting formulation of insulin aspart, the same insulin molecule found in NovoLog (Novolog), but reformulated with two added ingredients that make it absorb faster after injection. Approved for use in adults and children with type 1 or type 2 diabetes, Fiasp is designed to better match the rapid blood-sugar spike that happens after eating. The idea is straightforward: get insulin into the bloodstream sooner so it can meet glucose as it arrives, not ten or fifteen minutes later.

What Makes Fiasp Different From Regular Insulin Aspart

The active insulin molecule in Fiasp is identical to the one in NovoLog. What sets Fiasp apart are two excipients added to the formulation: niacinamide (a form of vitamin B3) and L-arginine (an amino acid). L-arginine serves as a stabilizing agent for the solution, while niacinamide does the heavy lifting on speed. It increases the initial abundance of insulin monomers at the injection site and causes a brief, localized widening of nearby blood vessels, both of which help shuttle the insulin into your circulation faster.

In practical terms, this means Fiasp starts working a few minutes sooner than standard insulin aspart. After a subcutaneous injection, serum insulin levels rise more steeply with Fiasp, which translates to a faster initial drop in blood sugar after a meal. The difference is not enormous in absolute terms, but for people who struggle with post-meal glucose spikes, even a few minutes of head start can meaningfully change the shape of their glucose curve.

Approved Uses and Who It Is For

Fiasp is indicated for mealtime (bolus) insulin coverage in people with type 1 or type 2 diabetes. You can inject it subcutaneously with a pen or syringe, or use it in an insulin pump. It is approved for adults and for children and adolescents.

The most common scenario is someone already using a rapid-acting insulin like NovoLog or Humalog at meals. Switching to Fiasp uses the same dosing approach: you calculate a bolus based on the carbs you are about to eat (or have just eaten) and your current blood sugar. The difference is that the insulin starts working sooner and peaks earlier, which matters most for high-glycemic meals that hit your bloodstream fast.

How Well It Works Compared to Standard Insulin Aspart

Multiple trials have compared Fiasp head-to-head against regular insulin aspart, and the pattern is consistent: Fiasp reduces after-meal glucose spikes more effectively, but overall long-term blood sugar control (measured by HbA1c) is only modestly different.

In a large phase III trial of people with type 1 diabetes followed for 52 weeks, Fiasp lowered HbA1c by about 0.1 percentage points more than standard insulin aspart. That is a small but statistically significant edge. Where Fiasp really stood out was the one-hour post-meal glucose reading, which dropped by roughly 1 mmol/L (about 16 mg/dL) more with Fiasp than with the standard formulation.

A meta-analysis pooling data from insulin pump users found an even larger advantage in post-meal control: people on Fiasp saw about a 1.35 mmol/L greater drop in one-hour post-meal glucose compared to those on regular insulin aspart, and a 1.19 mmol/L advantage at the two-hour mark.

For people with type 2 diabetes, the picture is slightly different. One review noted that while Fiasp provides a greater glucose-lowering effect within the first 20 minutes after injection, the overall HbA1c reductions were similar between Fiasp and standard insulin aspart in the type 2 population. This makes sense: type 2 diabetes often involves slower meal absorption patterns and residual insulin production, so the speed advantage may matter less on a day-to-day basis than it does in type 1.

Real-world data from a study following over 400 people with type 1 diabetes using continuous glucose monitors showed that switching to Fiasp improved time in range (the percentage of the day spent between 70 and 180 mg/dL) from about 50% to 55.5% over 12 months, equivalent to roughly 75 extra minutes per day in range. Time spent in dangerous low blood sugar territory did not increase.

⁴

Fiasp in Insulin Pumps and Closed-Loop Systems

One of the most interesting applications for Fiasp is in automated insulin delivery systems, sometimes called hybrid closed-loop or “artificial pancreas” systems. These devices pair a continuous glucose monitor with a pump that adjusts insulin delivery automatically. In theory, a faster insulin should let the algorithm respond more nimbly to rising glucose, reducing the lag that frustrates many pump users after meals.

Early results were promising. In a crossover study using the Medtronic 670G system, people using Fiasp spent about 26 more minutes per day in the target range compared to when they used standard insulin aspart, and had a larger reduction in one-hour post-meal glucose during a standardized meal test.

⁵

Simulation studies modeling thousands of virtual patients predicted that Fiasp would improve time in range by about 2.2 percentage points while simultaneously reducing time spent below 70 mg/dL by about 0.6 percentage points, and lowering mean post-meal glucose by roughly 5 mg/dL.

⁶

However, the picture got more nuanced as larger and more rigorous trials rolled in. A double-blind, multinational crossover study in adults with type 1 diabetes found that time in range with a hybrid closed-loop system was essentially identical between Fiasp and standard insulin aspart (75% for both). Where Fiasp did show a clear benefit was in hypoglycemia: time spent below 3.9 mmol/L (about 70 mg/dL) was reduced, and every lower hypoglycemia threshold tested also favored Fiasp.

⁷

An important point emerges from simulation research: simply dropping Fiasp into a pump system tuned for standard insulin aspart may not unlock its full potential. When the pump algorithm is adapted to account for the faster action profile, the improvements in time in range become substantially larger. One in-silico study estimated that optimized settings could boost time in range by more than 5 percentage points with Fiasp under closed-loop conditions.

⁸

Side Effects and Safety Profile

Fiasp’s side effect profile is broadly similar to that of other rapid-acting insulins. The most common risk is hypoglycemia (low blood sugar), which is a concern with any insulin product. In the clinical trials, rates of severe or serious hypoglycemia with Fiasp were comparable to standard insulin aspart.

One area where Fiasp has earned a reputation, particularly among pump users, is injection-site reactions. Some people experience more redness, swelling, or irritation at the infusion site compared to regular insulin aspart. This is likely related to the niacinamide component, which causes local blood vessel dilation as part of its absorption-speeding mechanism. The reactions are typically mild and tend to settle over time, but they have led some pump users to switch back.

Regarding post-meal lows specifically, a real-world study found that ultra-rapid insulins like Fiasp were associated with a lower risk of late post-meal hypoglycemia compared to standard rapid-acting insulins, particularly when the insulin was injected at delayed timing after a meal.

⁹

This finding makes intuitive sense: because Fiasp acts and clears faster, the late-lingering insulin effect that can cause blood sugar to drop hours after a meal is reduced. For people who frequently experience lows two to four hours after eating, this could be a meaningful safety advantage.

Using Fiasp in Hospitalized Patients

Most of the research on Fiasp focuses on outpatient self-management, but a study comparing Fiasp with NovoLog in hospitalized patients with type 2 diabetes found that the four-hour post-meal time in range (100 to 180 mg/dL) was 45% in the Fiasp group versus 36% in the NovoLog group. Other glycemic measures and hypoglycemia rates were similar between the two.

¹⁰

Hospital settings pose unique challenges for mealtime insulin because patients eat unpredictably, trays arrive at irregular times, and dosing often happens long before or after the food appears. A faster-acting insulin could help cushion some of that timing mismatch, though this is still an area being explored rather than standard practice.

Fiasp in Children and Adolescents

Managing mealtime insulin in young children is notoriously tricky. A toddler might eat three bites, declare they are done, and leave the rest. Giving a full dose of pre-meal insulin in that scenario risks a dangerous low. Some parents resort to injecting after the meal so they know how much the child actually ate, even though that delays the insulin’s peak.

A trial in preschool children with type 1 diabetes compared pre-meal and post-meal injection of Fiasp and found no significant differences in the frequency of clinical, severe, or serious hypoglycemia between the two approaches.

¹¹

For families dealing with unpredictable eaters, the ability to dose Fiasp right after a meal without a significant penalty in glucose control or added hypoglycemia risk can be a practical relief. With standard rapid-acting insulin, post-meal dosing tends to result in a wider glucose excursion because the insulin simply cannot catch up to the carbs.

Longer-term data from pediatric centers have been encouraging. A Portuguese center found that switching children with type 1 diabetes to Fiasp on pumps significantly improved time in range from 42% to 54% and reduced time above range from 52% to 40%, with no increase in hypoglycemia. Adolescents, who often have the toughest time with glucose control, also saw meaningful improvements.

¹²

That said, the story is not uniformly positive across all pediatric groups. A double-blind crossover study in very young children (ages 1 to 7) using the CamAPS FX hybrid closed-loop system found no significant difference in time in range between Fiasp and standard insulin aspart, with both achieving about 64 to 65%. No safety concerns emerged, but the expected advantage did not materialize in that tightly controlled automated setting.

¹³

A single-center study using real-world data in children and adolescents on pumps found that Fiasp did increase time in range and decreased time in hyperglycemia, though total daily insulin dose also went up.

¹⁴

Fiasp During Pregnancy

Pregnancy with diabetes demands extremely tight blood sugar control because sustained high glucose harms the developing fetus. A faster-acting insulin might seem like an obvious advantage in that context, but a randomized controlled trial (the Copenfast trial) compared Fiasp with standard insulin aspart in pregnant women with type 1 or type 2 diabetes and found similar outcomes. Mean HbA1c at 33 weeks of gestation was about 6.0% in the Fiasp group and 6.1% in the insulin aspart group, a difference that was not statistically significant. Birthweight scores were also similar, and no additional safety issues were identified with Fiasp.

¹⁵

The practical takeaway is that Fiasp can be used during pregnancy with no known additional risk, but it should not be expected to dramatically change pregnancy outcomes compared to standard insulin aspart. For women already comfortable with Fiasp before becoming pregnant, there is no need to switch away. For those hoping it would solve the extreme glucose variability of pregnancy, the trial data suggest it helps, but is not transformative.

Cost and Availability

Insulin pricing is a sore subject for many people with diabetes, and ultra-rapid formulations sometimes carry a premium. In the UK, a health-economic analysis found that switching from standard insulin aspart to Fiasp was cost neutral for the National Health Service, with the two formulations priced identically for vials and pen cartridges. Patients switching from the NovoRapid FlexPen to Fiasp in the FlexTouch pen device actually got an upgraded pen at no additional cost.

¹⁶

Pricing varies significantly by country and insurance plan. In the United States, the list price of Fiasp has historically been in the same range as NovoLog, but what you actually pay depends on your insurance formulary, pharmacy benefit manager, and whether you qualify for manufacturer discount programs. Some insurance plans prefer one rapid-acting insulin over another, and getting coverage for Fiasp may require a prior authorization showing you have tried standard rapid-acting insulins first. If you are considering a switch, checking your plan’s formulary before committing is worth the phone call.

Fiasp Versus Lyumjev

Fiasp is not the only ultra-rapid insulin on the market. Lyumjev (insulin lispro-aabc), made by Eli Lilly, takes the same general approach: reformulating an existing rapid-acting insulin (in this case lispro, the molecule in Humalog) with additives that speed absorption. Lyumjev uses treprostinil and citrate as its absorption accelerators rather than niacinamide and L-arginine.

Head-to-head trials directly comparing Fiasp and Lyumjev are limited, and most clinicians choose between them based on which base insulin molecule the patient is already using, insurance coverage, and personal tolerance. Both aim to reduce post-meal glucose spikes compared to their parent formulations, and both achieve that goal to a roughly similar degree. Some people tolerate one better than the other at the injection or infusion site. If you are experiencing site reactions with one, it may be worth trying the other, since the absorption-enhancing additives are chemically different.

Practical Tips for People Switching to Fiasp

If your provider has suggested switching from a standard rapid-acting insulin to Fiasp, a few things are worth keeping in mind. The dose in units does not typically need to change, since the insulin molecule is the same. What may change is timing. Many people who took their bolus 10 to 15 minutes before eating with standard insulin aspart find they can dose closer to the start of the meal, or even right as they sit down, with Fiasp.

For pump users, you may need to adjust your infusion site rotation schedule if you notice more irritation. Changing the site every two days rather than three, or rotating to areas with more subcutaneous tissue, can help. If you use a hybrid closed-loop system, talk to your care team about whether the pump’s settings need adjustment. As the simulation research showed, algorithms tuned for standard insulin may not fully exploit Fiasp’s faster profile, and small tweaks can make a real difference.

Monitor your blood sugars more frequently for the first week or two after switching, especially in the two-to-four-hour window after meals. Fiasp’s faster onset means it also clears sooner, and stacking boluses (giving a correction dose too soon after a meal bolus) can lead to unexpected lows. Conversely, if you are used to a slow tail effect from standard rapid-acting insulin that kept your glucose down between meals, you may notice your sugar drifting up a bit sooner after Fiasp clears. That is the normal tradeoff of a faster profile and not a sign something is wrong.